Needham Rates MapLight Therapeutics (MPLT) buy, $42 Price Target
Needham maintained its buy rating on MPLT and set a $42 price target, a 37.84% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Needham rated MapLight Therapeutics, Inc. ($MPLT) "buy" with a $42 price target on June 22, 2026.
Since the rating, $MPLT is up 15.1% after 1 week, up 18.5% after 1 month and down 74.2% to date (from the $29.79 close on Jun 22, 2026).
MPLT
MapLight Therapeutics, Inc.
Key Points
- Needham reiterated its buy rating on MPLT with a price target of $42 on June 22, 2026.
- Needham's $42 price target implies 37.84% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $30.47 share price.
- Shares of MPLT traded near $30.47 on Monday, reflecting ongoing interest from institutional investors.
- Major holders like BlackRock and Blue Owl Capital have significantly increased their positions in MPLT.
Get $MPLT trade alerts by text
We text you when insiders, Congress or big funds trade $MPLT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MapLight Therapeutics, Inc. alert may contain errors. Disclosures
On June 22, 2026, Needham reiterated its buy rating on MPLT, setting a price target of $42. This update reflects continued confidence in the company's potential, as MPLT shares traded around $30.47 on Monday.
Needham vs. the S&P 500
Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in MPLT
Several institutional investors have shown varying levels of interest in MPLT. Novo Holdings A/S and FCPM III Services B.V. maintained their positions without changes, holding 3,686,622 and 3,226,400 shares, respectively. T. Rowe Price Investment Management added 2,757 shares, bringing its total to 2,801,937 shares valued at approximately $56.96 million, marking a slight 0.1% increase. Goldman Sachs Group increased its holdings by 57,705 shares to 1,994,873, reflecting a 3% growth. BlackRock, Inc. significantly boosted its stake by 244,217 shares, resulting in 1,339,731 shares worth about $27.24 million, a 22.3% increase. Blue Owl Capital Holdings LP made the most notable move, adding 678,871 shares to reach 1,005,929 shares, a 207.6% increase.
Analysts Set New Price Targets
Needham maintained its buy rating on MPLT with a $42 price target on June 22, 2026. Stifel also maintained a buy rating earlier in June, with a target of $36. UBS and Craig-Hallum initiated coverage in late May with buy ratings and targets of $48 and $43, respectively. HC Wainwright & Co. set a $45 target with a buy rating in early May. These ratings highlight a generally positive sentiment among analysts.
Bottom Line
Needham's reiterated buy rating and $42 price target underscore ongoing confidence in MPLT's prospects. The stock's current trading price and recent institutional activity suggest a growing interest in its potential. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and they reflect opinions at a specific point in time.
$MPLT price target
MapLight Therapeutics, Inc. daily closes and this analyst's $42 target. Not advice.
Related Filing Alerts
Source: Needham's rating change on $MPLT (Jun 22, 2026). Written by software, not financial advice. How we make alerts